Impact of NSCLC metabolic remodeling on immunotherapy effectiveness

Biomarker Research

Table 3 Metabolic reprogramming immunotherapies in the preclinic

Inhibitors	Targets	Cancer types	References
Dichloroacetic acid	PDH	breast cancer	[111]
Dimethyl fumarate	G6PD	breast cancer	[112]
L-Arg bacteria	L-arginine	Colon Cancer	[113]
oxamate	LDH	lung cancer cells	[114]
CB-839	Glutaminase	Melanoma mouse	[115]
Protein phosphatase 2A	PPP	SCLC	[116]
AZD3965	MCT1	TC-1 cancer cells	[117]

ISSN: 2050-7771